Human Genome Epidemiology Literature Finder
Records 1 - 19 (of 19 Records) |
Query Trace: Neutropenia and XRCC1[original query] |
---|
A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006 Nov 1 (9): 972-8. Pillot Giancarlo A, Read William L, Hennenfent Kristin L, Marsh Sharon, Gao Feng, Viswanathan Avinash, Cummings Kristopher, McLeod Howard L, Govindan Ramaswa |
A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007 Mar 2 (3): 197-202. Petty W Jeffrey, Knight Sommer N, Mosley Libyadda, Lovato James, Capellari James, Tucker Robert, Blackstock A William, Miller Mark Steven, Miller Antonius |
Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Mar 14 (6): 1788-96. Hoskins Janelle M, Marcuello Eugenio, Altes Albert, Marsh Sharon, Maxwell Taylor, Van Booven Derek J, Paré Laia, Culverhouse Robert, McLeod Howard L, Baiget Montserr |
Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. The pharmacogenomics journal 2010 Feb 10 (1): 54-61. Khrunin A V, Moisseev A, Gorbunova V, Limborska |
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. Pharmacogenomics 2009 Jul 10 (7): 1139-46. Hoskins Janelle M, Rosner Gary L, Ratain Mark J, McLeod Howard L, Innocenti Federi |
Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Jun 27 (17): 2863-73. Goekkurt Eray, Al-Batran Salah-Eddin, Hartmann Jörg T, Mogck Ulrike, Schuch Gunter, Kramer Michael, Jaeger Elke, Bokemeyer Carsten, Ehninger Gerhard, Stoehlmacher J |
Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer. Pharmacogenomics 2010 Oct 11 (10): 1377-87. Sakano Shigeru, Hinoda Yuji, Sasaki Miwa, Wada Takashi, Matsumoto Hiroaki, Eguchi Satoshi, Shinohara Asano, Kawai Yoshihisa, Hara Tomohiko, Nagao Kazuhiro, Hara Takahiko, Naito Katsusuke, Matsuyama Hideya |
DNA repair gene XPD and XRCC1 polymorphisms and the risk of febrile neutropenia and mucositis in children with leukemia and lymphoma. Leukemia research 2012 May 36 (5): 565-9. Ozdemir Nihal, Celkan Tiraje, Bar?? Safa, Batar Bahad?r, Güven Mehm |
DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012 Oct 7 (10): 1609-17. Er?ulj Nina, Kova? Viljem, Hmeljak Julija, Franko Alenka, Dodi?-Fikfak Metoda, Dolžan Vi |
Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer chemotherapy and pharmacology 2013 Jun 71 (6): 1463-72. Cortejoso Lucía, García María I, García-Alfonso Pilar, González-Haba Eva, Escolar Fernando, Sanjurjo María, López-Fernández Luis |
Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. Cancer chemotherapy and pharmacology 2013 Jan . Lee KH, Chang HJ, Han SW, Oh DY, Im SA, Bang YJ, Kim SY, Lee KW, Kim JH, Hong YS, Kim TW, Park YS, Kang WK, Shin SJ, Ahn JB, Kang GH, Jeong SY, Park KJ, Park JG, Kim TY |
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. Scientific reports 2014 4 6828. Ruzzo Annamaria, Graziano Francesco, Galli Fabio, Giacomini Elisa, Floriani Irene, Galli Francesca, Rulli Eliana, Lonardi Sara, Ronzoni Monica, Massidda Bruno, Zagonel Vittorina, Pella Nicoletta, Mucciarini Claudia, Labianca Roberto, Ionta Maria Teresa, Veltri Enzo, Sozzi Pietro, Barni Sandro, Ricci Vincenzo, Foltran Luisa, Nicolini Mario, Biondi Edoardo, Bramati Annalisa, Turci Daniele, Lazzarelli Silvia, Verusio Claudio, Bergamo Francesca, Sobrero Alberto, Frontini Luciano, Magnani Mau |
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer chemotherapy and pharmacology 2015 Apr 75 (4): 763-72. Joerger M, Huitema A D R, Boot H, Cats A, Doodeman V D, Smits P H M, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny T D, Beijnen J H, Schellens J H |
Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. European journal of cancer (Oxford, England : 1990) 2018 8 102 31-39. Madi Ayman, Fisher David, Maughan Timothy S, Colley James P, Meade Angela M, Maynard Julie, Humphreys Vikki, Wasan Harpreet, Adams Richard A, Idziaszczyk Shelley, Harris Rebecca, Kaplan Richard S, Cheadle Jeremy |
Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh. Molecular biology reports 2020 Sep . Bushra Most Umme, Rivu Sanzana Fareen, Sifat Ali Ehsan, Nahid Noor Ahmed, Ahmed Maizbha Uddin, Al-Mamun Mir Md Abdullah, Apu Mohd Nazmul Hasan, Islam Md Siddiqul, Islam Md Reazul, Islam Mohammad Safiqul, Hasnat Ab |
Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). Pharmacogenetics and genomics 2021 Jun . Patel Jai N, Jiang Chen, Owzar Kouros, Mulkey Flora, Luzum Jasmine A, Mamon Harvey J, Haller Daniel G, Dragovich Tomislav, Alberts Steven R, Bjarnason Georg, Willet Christopher G, Niedzwiecki Donna, Enzinger Peter, Ratain Mark J, Fuchs Charles, McLeod Howard |
Pharmacogenomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: the predict IR study. Cancer chemotherapy and pharmacology 2021 Mar . Michael Michael, Liauw Winston, McLachlan Sue-Anne, Link Emma, Matera Annetta, Thompson Michael, Jefford Michael, Hicks Rod J, Cullinane Carleen, Hatzimihalis Athena, Campbell Ian G, Rowley Simone, Beale Phillip J, Karapetis Christos S, Price Timothy, Burge Mathew |
Low-Cost Genetic and Clinical Predictors of Response and Toxicity of Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer. Dose-response : a publication of International Hormesis Society 0 20 (2): 15593258221111666. Spasic Jelena, Cavic Milena, Stanic Nemanja, Zaric Bojan, Kovacevic Tomi, Radosavljevic Davorin, Nagorni-Obradovic Ljudmi |
Genetic Polymorphisms of DNA Repair Genes and their Influence on Paclitaxel based Chemotherapy Induced Toxicity Reactions in Breast Cancer Patients. Asian Pacific journal of cancer prevention : APJCP 2024 12 25 (12): 4281-4292. Kailas D Datkhile, Prajakta N Reur, Shivani R Kale, Rashmi A Gudur, Suresh J Bhosale, Anand K Gud |
- Page last reviewed:Feb 1, 2024
- Content source: